---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-117148"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T22:12:57.370560+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics Q3 net loss narrows to $6.9M; FDA grant awarded for AML trial

## Summary
- Net loss of $6.9M in Q3 2022, compared to $12.4M loss in Q3 2021.
- Cash and equivalents $18.1M as of Sept 30, 2022; grant income $1.0M, related party service revenue $2.95M.
- Awarded $2M FDA Orphan Products Grant to support Phase 2 ARTEMIS trial of MT-401 in post-transplant AML.
- All six patients in Cohorts 4/5 treated with new manufacturing process; no DLTs; efficacy data expected by year-end.
- FDA cleared IND for Phase 1 MT-601 in relapsed/refractory non-Hodgkin lymphoma; first patient expected Q1 2023.

## SEC filing metadata
- accession: 0001104659-22-117148
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465922117148/0001104659-22-117148-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465922117148/tm2223865d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-117148
- JSON: https://secwatch.observer/filing/0001104659-22-117148.json
- Plain text: https://secwatch.observer/filing/0001104659-22-117148.txt

## Key facts
- Earnings Releases
  Marker Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income $6.9 million.
  - Period: the quarter ended September 30, 2022
  - Net income: $6.9 million
  - Result: reported results
  source text: Marker reported a net loss of $6.9 million for the quarter ended September 30, 2022, compared to a net loss of $12.4 million for the quarter ended September 30, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1094038/000110465922117148/0001104659-22-117148-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.